Pharma Medical News

Pharma

Become a Member Today!

Email
Password
Remember me
Forgot your Password?
Invite Code?

Home
General Pharma

Messages

Conferences

Jobs

Newsletters

My Library

Topics in
Pharma

Biotechnology

Conferences/Meetings

Drug Trials

Drug/Product Approvals

Execs on the Move

Financial Reports

M&A/Partnerships

Marketing/Media/ROI

Medical Devices/Products

Physician/Patient Trends

Popular Press

Regulatory Issues

Research & Development

Help

Resource Center

RSS News Feeds

Send Newsletter
to a Friend

The Best of 2008
D Scott Cunningham MD, PhD, MDLinx

See all

Article Summary

Click the title below to leave the MDLinx Network and go to the Journal's Website

Corcept Therapeutics Announces Negative Results From the First of Three Phase 3 Studies Evaluating CORLUX(R) for Treating the Psychotic Features of Psychotic Major Depression
Corporate News Releases - The Healthcare Sales & Marketing Network, 08/28/06

Email This Article

Save in My Library

Free Full Text

Corcept Therapeutics, Incorporated announced that the first of its three Phase 3 trials evaluating CORLUX for treating the psychotic features of Psychotic Major Depression (PMD) was negative. Study 07 was a randomized, double-blind, placebo-controlled study

Read a Different Specialty

Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT

Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology

Orthopedics
Pediatrics
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology

Profession Index

Dentist
Hospital Administrator
Nurse

Medical Students
Nurse Practitioner
Pharma/Drug Marketer

Pharmacist
Physician
Physician Assistants

Article Search

Keyword:

Search:

Published within:

Sort By:
Date Relevance